Ovarian damage from chemotherapy and current approaches to its protection

N. Spears 1,*, F. Lopes 1, A. Stefansdottir 1, V. Rossi 2, M. De Felici 2, R.A. Anderson 3, and F.G. Klinger 2,*

1Biomedical Sciences, University of Edinburgh, Edinburgh UK  2Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy  3MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh UK

*Correspondence. N. Spears, E-mail: norah.spears@ed.ac.uk orcid.org/0000-0002-5604-1974; F.G. Klinger, E-mail: klinger@uniroma2.it orcid.org/0000-0001-6744-0850

Submitted on July 2, 2019; resubmitted on July 18, 2019; editorial decision on July 23, 2019

TABLE OF CONTENTS

• Introduction
• Methods
• Dynamics of the ovarian reserve
• Ovarian damage from chemotherapy and its potential protection
  • Cyclophosphamide
  • Cisplatin
  • Doxorubicin
  • Protective agents acting independently of specific chemotherapy drug actions
• Conclusion

BACKGROUND: Anti-cancer therapy is often a cause of premature ovarian insufficiency and infertility since the ovarian follicle reserve is extremely sensitive to the effects of chemotherapy and radiotherapy. While oocyte, embryo and ovarian cortex cryopreservation can help some women with cancer-induced infertility achieve pregnancy, the development of effective methods to protect ovarian function during chemotherapy would be a significant advantage.

OBJECTIVE AND RATIONALE: This paper critically discusses the different damaging effects of the most common chemotherapeutic compounds on the ovary, in particular, the ovarian follicles and the molecular pathways that lead to that damage. The mechanisms through which fertility-protective agents might prevent chemotherapy drug-induced follicle loss are then reviewed.

SEARCH METHODS: Articles published in English were searched on PubMed up to March 2019 using the following terms: ovary, fertility preservation, chemotherapy, follicle death, adjuvant therapy, cyclophosphamide, cisplatin, doxorubicin. Inclusion and exclusion criteria were applied to the analysis of the protective agents.

OUTCOMES: Recent studies reveal how chemotherapeutic drugs can affect the different cellular components of the ovary, causing rapid depletion of the ovarian follicular reserve. The three most commonly used drugs, cyclophosphamide, cisplatin and doxorubicin, cause premature ovarian insufficiency by inducing death and/or accelerated activation of primordial follicles and increased atresia of growing follicles. They also cause an increase in damage to blood vessels and the stromal compartment and increment inflammation. In the past 20 years, many compounds have been investigated as potential protective agents to counteract these adverse effects. The interactions of recently described fertility-protective agents with these damage pathways are discussed.

WIDER IMPLICATIONS: Understanding the mechanisms underlying the action of chemotherapy compounds on the various components of the ovary is essential for the development of efficient and targeted pharmacological therapies that could protect and prolong female fertility. While there are increasing preclinical investigations of potential fertility preserving adjuvants, there remains a lack of approaches that are being developed and tested clinically.
Introduction

The effects of cancer and its treatment on female reproductive function are increasingly well documented. Overall, compared to the general population, women are 38% less likely to have a pregnancy after cancer diagnosis and treatment, with all diagnostic groups of cancer being associated with a reduction in the likelihood of subsequent pregnancies (Anderson et al., 2018). Given this situation, there is now a pressing need to develop methods to protect patients from the damaging effects of treatment. This review therefore assesses the effectiveness of potential treatments to protect the ovary against chemotherapy-induced damage, with the work to date reported for only pre-clinical studies, primarily animal models.

Over the last several decades, cervical cancer and breast cancer have had the greatest impact on reducing the number of pregnancies achieved, due to a combination of their high prevalence, the marked effect of their associated treatments and patient age. Recent years have seen improvements for these two particular malignancies and for other cancers, such as Hodgkin lymphoma, although some diagnoses have seen little, if any, change in their impact on subsequent chances of pregnancy (Anderson et al., 2018). While radiotherapy and surgery can have very significant adverse effects on female reproductive function, this review focuses on the adverse effects of chemotherapy and on possible approaches to reduce its impact. The adverse effects of chemotherapy on ovarian function have long been recognised (Fig. 1A) and there are increasingly detailed data documenting the effects of different regimens on short-term markers of ovarian function, longer-term fertility and risk of early menopause (Jayasinghe et al., 2018; van Dorp et al., 2018). The impact of estrogen deficiency as a result of loss of ovarian function on quality of life, bone function and cardiovascular and neurological health are also critical aspects of the longer-term effects of chemotherapeutic damage to the ovaries (European Society of Human Reproduction and Embryology, 2015; Lobo, 2017). This has led to the development of methods for female fertility preservation (Anderson et al., 2015). The advent of oocyte vitrification was a key advancement in the ability to successfully preserve postpubertal female fertility (Argyle et al., 2016), while ovarian tissue cryopreservation has had a growing evidence base with increasing documentation of success rates; it is feasible prior to puberty and is now recognised as an established rather than an experimental form of treatment in some countries (Donnez and Dolmans, 2017).

Alongside the cryopreservation of gametes, a number of approaches have also been explored with the aim of protecting ovarian follicles and the oocytes they contain from chemotherapy-induced damage; these are reviewed in this paper.

The use of GnRH analogues to protect ovarian function has been the subject of a number of large randomised controlled trials, particularly in breast cancer, and these results have been widely analysed and discussed. It is now clear that this approach does reduce the prevalence of premature ovarian insufficiency (POI) in women treated for breast cancer (Lambertini et al., 2018) although it appears that relatively little ovarian function, as reflected by anti-Müllerian hormone (AMH), may be preserved by this approach (Leonard et al., 2017). The effectiveness of this approach in other cancers is not clear, with the largest trial in women with lymphoma showing no apparent benefit (Demeestere et al., 2016). Additionally, the benefits of this approach in terms of subsequent pregnancy and the avoidance of the consequences of POI, e.g., in bone health, remain to be clearly demonstrated in trials designed with those outcomes as a primary objective. As this approach has been extensively reviewed and is the subject of a number of meta-analyses (including Del Mastro et al., 2014; Lambertini et al., 2018; Vitek et al., 2014), it will not be discussed further here.

Methods

A thorough search was carried out for relevant articles in order to carry out an extensive study on the ovarian damage induced by chemotherapy and on new approaches to its protection. All authors contributed to the search and to establish the inclusion and exclusion criteria. As an analysis of published data, approval of an ethics committee is not relevant.

The research was performed using PubMed and Medline as sources, up to March 2019. The following keywords were used: chemotherapy, cyclophosphamide (CPM), cisplatin (CIS), doxorubicin (DOX), fertility preservation, adjuvant therapy, ovary, follicle death.

For the sections concerning the protective agents, the selection of the papers was performed using PRISMA guidelines (Moher et al., 2009), as described below and as reported in a PRISMA diagram (Fig. 2). The research was performed using PubMed and Medline as sources, up to March 2019. The following keywords were used: chemotherapy, alkylating agents, anthracycline, female, ovary, adjuvant therapy, fertoprotective therapy, fertility preservation, follicle death. All relevant articles were carefully evaluated. Initially, titles and abstracts were assessed to evaluate the eligibility of the studies. After this selection, the authors proceeded with the complete reading of the papers to identify those relevant for final inclusion. Reference lists of these papers were checked to identify other studies that should be included in this review. Only published articles, written in English and peer-reviewed, were included. The search included both animal and human studies. No restriction to any publishing year was applied, even though the search showed that relevant papers were dated starting from year 2000. Manuscripts were selected concerning protective agents towards CPM, cisplatin and doxorubicin on the ovary, while those concerning protective agents only against other chemotherapeutic drugs and radiotherapy were excluded from the review. Manuscripts describing no effect or adverse effects of the agents were included. Reports only presented as conference proceedings were excluded.

Dynamics of the ovarian reserve

Underpinning the interpretation of the impact of chemotherapy on ovarian function are the established findings that oogonia enter meiosis during fetal life, and that the primordial follicle (PMF) pool is formed early on, in utero in humans and around the time of birth in rodents. These PMFs are located around the edge of the ovarian cortex, an area with relatively little vasculature (Delgado-Rosas et al., 2009). There is a
Figure 1 The damaging effects of chemotherapy drugs on the ovary and potential protectants against that damage. (A) Chemotherapy drugs can damage the ovary by inducing prenatal loss of oogonia, direct loss of primordial follicles, accelerated activation of primordial follicles, follicular atresia, stromal tissue damage, damage to the vasculature or inflammation. (B) Protectants examined to date have been shown to protect against all ovarian damage pathways other than that to stromal tissue. Other protectants are designed to reduce drug delivery to the ovary. PMF: primordial follicle; TRNS: transitional follicle.
Figure 2 PRISMA flow diagram of literature search methodology for publications examining the effectiveness of potential fertility protective agents. Search results, study screening, and study inclusion, following a review of the literature carried out using PRISMA guidelines (Moher et al., 2009). Selected key words were searched in PubMed until March 2019, with 24 additional references identified through other sources, resulting in examination of 1357 papers. After the analysis of all publications for the inclusion and exclusion criteria, 40 articles from the initial search were used in this review.
steady rate of activation of PMFs throughout the reproductive lifespan, with its depletion resulting in the menopause. The biochemical pathways that regulate this activation of PMFs include growth factors acting through pathways, including the PI3K/PTEN/Akt pathway and the Hippo pathway (Ernst et al., 2017; Kawamura et al., 2013; Grosbois and Demeester, 2018). The Akt pathway is of particular importance here, because it is modulated by both chemotherapy drugs and protectants, as discussed below. This pathway acts via FOXO3a, which in rodents is considered to be a key transcription factor in the maintenance of resting follicles, with activation of a PMF marked by translocation of FOXO3a from the nucleus to the cytoplasm (John et al., 2008; Chang et al., 2015). Activity of this PI3K/PTEN/Akt pathway within oocytes is a critical determinant of the size of the remaining PMF pool (Reddy et al., 2008). Inhibitory factors are also important, including AMH (Durlinger et al., 1999), but how these pathways and factors interact to provide precise regulation of the activation of PMFs remains unclear.

Given the poor vasculature in the outer layer of the ovarian cortex where the PMFs are located (Fig. 1A), it is possible that PMFs are exposed to lower concentrations of chemotherapy drugs than the well-vascularised later-stage follicles, as the drugs primarily reaching PMFs via diffusion. The extent to which PMFs can be lost directly through atresia or apoptosis is also unclear, although genetic studies have documented a number of factors relating to apoptosis which appear to have major roles in the regulation of the size of the PMF pool. Some of these, such as the apoptotic regulator PUMA (Nguyen et al., 2018; Myers et al., 2014), may be future targets for intervention in the regulation of PMF loss, since they have particular roles in regulating DNA damage-induced oocyte death once follicle growth has been initiated, at least in the mouse (discussed more fully below), although its role in humans is not yet known. The great majority of follicles will become atretic at some stage during the follicular growth phase, and the high proliferation rate of granulosa cells in growing follicles makes them a sensitive target of many chemotherapy agents. Furthermore, the need to maintain chromosomal and DNA integrity in the oocyte, from PMF formation all the way through to subsequent ovulation and thus potentially for decades, also renders the oocyte itself a key site for the adverse effects of DNA-damaging chemotherapy agents.

Regulation of the rate at which PMFs undergo activation has an added complexity arising from the interaction between PMFs and the population of growing follicles. AMH produced by growing follicles is thought to have an important inhibitory effect on the rate of PMF activation (Durlinger et al., 1999), although evidence for this is much clearer in the rodent than in the human or in other larger monovulatory mammalian species (Schmidt et al., 2005; Campbell et al., 2012). Inhibitory interactions between neighbouring PMFs slowing down the rate of activation have also been proposed (Da Silva-Buttkus et al., 2009); since the spatial distributed of PMFs is in clusters, particularly in the adult ovary (Gayan et al., 2015), loss of some PMFs would reduce the inhibitory influence on other PMFs within the cluster. As such, loss of PMFs in chemotherapy-treated ovaries could be a result of a direct pathway whereby PMFs become damaged and die and/or due to an indirect pathway resulting in accelerated PMF activation, a loss that can be thought of as an accelerated version of ovarian ageing. Indirect loss of PMFs as a result of accelerated activation could be due to a loss of inhibitory factors from growing follicles that have undergone atresia (Kalich-Philosoph et al., 2013; Roness et al., 2013). It is important to bear in mind that chemotherapy drugs can also have damaging effects on the ovarian stroma and vasculature (Oktem and Oktay, 2007; Meir et al., 2007), either of which can, in turn, impact negatively on the health of the follicular reserve, as well as impairing normal follicle development.

Together, these considerations of both direct and indirect effects on follicle pools at different stages of development provide a basis for interpretation of the effects of chemotherapy and thus approaches towards prevention of these adverse effects. Few such studies have examined effects on human ovary, with most using rodent models. As such, there is a pressing need for the effectiveness and safety of the most promising potential protectants to be determined in the human, a crucial step towards any subsequent clinical development. This will require studies to ensure that the protectants do not interfere with the efficacy of the cancer treatment and that they do not impair the developmental competence of oocytes or lead to the survival of oocytes with DNA damage in the form of genetic or epigenetic mutations (Clarke and Vieux, 2015; Kirsch-Volders et al., 2019).

**Ovarian damage from chemotherapy and its potential protection**

The effects of chemotherapy treatment on future fertility are relevant for both childhood cancers and those that affect women up to the age of menopause. The most common childhood cancers are leukaemia (around 26% of all registered cases), followed by central nervous system tumours and lymphomas. In young women, carcinomas (around 30% of cases), followed by lymphomas, melatomas and central nervous system tumours are most frequent, while in older pre-menopausal women, the relevant diseases are breast cancer (over 40% of cases), followed by melanoma, cervix and central nervous system tumours (https://seer.cancer.gov/statistics; https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/age-heading-Two; Cronin et al., 2018). Chemotherapy drugs are also used in the treatment of a wide range of non-malignant diseases, including auto-immune illnesses, with chemotherapy conditioning prior to stem cell transplant being increasingly used for haematological conditions, such as sickle cell anaemia. With such an extensive group of diseases, treatment can involve administration of a wide range of chemotherapeutic classes and drugs, including alkylating agents (CPM, busulphan and others); alkylating-like platinum complexes (such as cisplatin [CIS]; anthracyclanes (including doxorubicin [DOX]); taxanes (docetaxel and others); topoisomerase inhibitors (such as etoposide); and vinca alkaloids (including vincristine).

The effects of chemotherapy drugs on female reproduction began to be reported in the 1970s, initially associated primarily with CPM treatment (see, for example, Miller et al., 1971; Fries et al., 1973; Koyama et al., 1977), with reports of amenorrhoea, ovarian suppression and follicle destruction. From early in the development of chemotherapy drug use, administration of one drug alone became rare, with patients instead being treated with drug combinations. Given this, it has become increasingly difficult to determine which particular drug is responsible for the fertility-damaging effects, with relatively little known about the ovarian toxicity of some drugs. Nonetheless, there is strong clinical evidence that ovarian damage is particularly severe after administration of alkylating and alkylating-like agents (Chow et al., 2016; van Dorp...
et al., 2018; Meirow and Nugent, 2001), while DOX, which is used to treat a wide range of cancers, is amongst the non-alkylating agents most closely linked to female reproductive problems (Bar et al., 2003; Green et al., 2009; Bedoschi et al., 2016; Bedoschi et al., 2019). Consequently, many of the chemicals currently being investigated as potential protectants have been specifically tested to ameliorate damage induced by CPM, CIS or DOX. As such, the mechanism of action of, and potential protection against damage by, each of these three drugs are examined in detail below. It should be borne in mind that other drugs also have moderate or strong ovarian toxicity, particularly the alkylating agent busulphan (Chow et al., 2016). Some potential protectants, such as AMH, should, in theory, be effective against a wide range of chemotherapy drugs and are discussed separately.

Cyclophosphamide
Action of cyclophosphamide (CPM) and main uses in treatment
CPM is an alkylating agent, capable of covalently binding alkyl groups to DNA. Alkylating agents, originally derived from the mustard gas chemical warfare agents, were the first drugs shown to result in tumour regression. CPM itself is a pro-drug, metabolised by cytochrome P450 in the liver to form 4-hydroxy-cyclophosphamide, which is in turn converted to phosphoramid mustard and acrolein. Phosphoramid mustard is the primary active metabolite (Flowchalk and Mattison, 1991; Madden and Keating, 2014), inducing DNA crosslinking that leads to the formation of adducts that prevent DNA replication. Phosphoramid mustard also affects mitochondria, leading to a reduction in transmembrane potential and cytosolic cytochrome c accumulation. CPM is used in the treatment of a wide range of cancers, particularly the more frequent childhood cancers, melanomas and breast cancer; including the treatment of pregnant cancer patients (Hahn et al., 2006). It is also used in the treatment of auto-immune diseases, such as systemic lupus erythematosus and rheumatoid arthritis.

Effect of CPM on the ovary

Human ovary studies. CPM was the first chemotherapy drug to be linked to amenorrhea/POI and ovarian dysfunction (Miller et al., 1971; Fries et al., 1973; Koyama et al., 1977), and it continues to be regarded as one of the most gonadotoxic agents (Overbeek et al., 2015; Yuksel et al., 2016; Luo et al., 2017; Pascuali et al., 2018). With CPM also administered to pregnant cancer patients, the effects of CPM on the developing ovary has also been investigated, with formation of fewer follicles formed (Fig. 1A) and acceleration of PMF activation (Ray and Potu, 2010; Comish et al., 2014). One recent study has demonstrated that maternal CPM exposure prior to conception can affect the competence of the offspring’s oocytes, which was associated with altered methylation of three imprinted genes (H19, Igf2r and Peg3) (Di Emidio et al., 2019).

Molecular pathways of CPM-induced ovarian damage
Most of our understanding of precisely how CPM induces ovarian damage has come from studies trying to prevent that damage (Table 1). As expected, given what is known about its action on cancer cells, there is clear evidence that CPM leads to an upregulation in apoptosis in the ovary, as is evident from the rapid induction of DNA breaks (Pascuali-Srader et al., 2015) and from a change in the expression levels of pro- and anti-apoptotic genes (Petrollo et al., 2011; Pascuali et al., 2018; Luo et al., 2019). Recent studies have demonstrated that the DNA damage-induced pro-apoptotic protein PUMA plays a key role in inducing oocyte apoptosis in rodents following CPM treatment (Nguyen et al., 2018), as is also the case following irradiation (Kerr et al., 2012). A decrease in production of antioxidant enzymes, such as superoxide dismutase, has also been shown (Khedr, 2015; Melekoglu et al., 2018). Work has also examined whether CPM stimulates the mTOR/PTEN/Akt pathway, resulting in accelerated PMF activation. Kalich-Philosoph et al. (2013) have shown induction of Akt, mTOR and FOXO3a within 24 h of CPM exposure. Increased phosphorylation of Akt and other parts in the pathway have also been shown by Goldman et al. (2017), although in that instance, the tissue was examined 7 days after the end of treatment. One study has now demonstrated that CPM specifically induces apoptosis in the oocytes of primordial follicles, while also not finding increased activation of such follicles (Luan et al., 2019). An inflammation response has been shown through increased levels of the pro-inflammatory cytokines IL-6 and -8 and TNFα alongside reduced levels of the anti-inflammatory IL-10, although this was in response to administration of both CPM and busulfan (Luo et al., 2017). CPM also leads, in mouse oocytes, to an increase in the expression of the cell redox state sensor SIRT1, as the result of the adaptive response to oxidative stress (Di Emidio et al., 2017). In fact, SIRT1 is involved in both inflammation and oxidative stress, by inhibiting
NF-κB signalling and stimulating the expression of antioxidants through FoxO transcription factors, respectively (Xie et al., 2013; Salmi

Agents used to protect ovaries from CPM-induced damage
Potential protectants from CPM-induced damage have been investigated to determine protection against direct loss of PMFs, accelerated activation of PMFs, increased atresia of growing follicles and damage to the ovarian vasculature (Fig. 1B, Table II). At present, only Sphingosine-1-phosphate (SIP) and tamoxifen have been examined in the human ovary (see below).

SIP and Ceramide 1 phosphate. Bioactive sphingolipids, SIP and ceramide 1 phosphate (C1P), produced through ceramide metabolism, are inhibitors of the ceramide-induced death pathway and regulate angiogenesis, vascular stability and permeability in a variety of tissues, in both physiological and pathological conditions (Bonnaud et al., 2007; Cuvillier et al., 1996). SIP prevents CPM-induced apoptotic follicle death in both human ovarian xenografts (Li et al., 2014; Meng et al., 2014) and isolated granulosa cells obtained from assisted reproduction techniques (Li et al., 2017). Intrabursal C1P administration ameliorates ovarian follicular and vascular development and restores fertility in CPM-treated mice, with reduced TUNEL staining and decreased cleaved caspase 3 and BAX expression, together clearly indicating a reduction in apoptosis in all follicles analysed (Pascuali et al., 2018).

AS101. The immunomodulator AS101 is a non-toxic, tellurium-based compound that modulates the PI3K/PTEN/Akt pathway, reducing the Akt and rpS6 phosphorylation that is induced by CPM (Makarovsky et al., 2003). It is used in clinical trials for neovascular age-related macular degeneration due to its immunomodulating characteristics and in the treatment of chemotherapy-induced thrombocytopenia and psoriasis. In vivo treatment of mice with AS101 lowers CPM-induced loss of PMFs, as well as apoptosis of granulosa cells in growing follicles, leading to improved reproductive outcomes (Kalich-Philosoph et al., 2013). Mice born to dams whose fertility is protected by AS101 treatment show no abnormalities, indicating that the quality of the rescued oocytes is also protected. Importantly, it has been demonstrated that not only does AS101 not interfere with the primary anti-neoplastic activity of CPM in vivo, but, in fact, it also may improve the efficiency of the anti-cancer activity of CPM, possibly due to reduced inflammation (Ronesi et al., 2016; Kalich-Philosoph et al., 2013; Kalechman et al., 1991; Ronesi et al., 2014).

Crocin. Crocin is a diapocarotenedioic acid, the main bioactive compound in saffron, which protects primordial and growing follicles from CPM-induced injury. Crocin can also provide protection against toxicant-induced oxidative stress along with underlying disorders in numerous organs, tissues and cells (Xi et al., 2007). Crocin administration (as with AS101) prevents an increase in SIRT1 expression, suggesting that preservation of the redox balance can help the ovary counteract CPM-induced ovarian damage (Di Emidio et al., 2017). Despite this, crocin and AS101 were not able to fully counteract effects on oocyte imprinting in offspring (Di Emidio et al., 2019).

mTORC inhibitors. mTOR is a serine/threonine kinase and a metabolic sensor that regulates cell growth, proliferation, autophagy and survival (Wullschlegler et al., 2006). Deletion of components of the mTOR pathway, including PTEN- and TSC1-negative regulators, can induce accelerated PMF activation in mice (Reddy et al., 2008; Adhikari et al., 2010; Chen et al., 2015). As such, in animal models, mTOR stimulators accelerate activation of PMFs, while mTOR inhibitors block the PMF-to-primary follicle transition (Sun et al., 2015). To determine if inhibition of the mTOR pathway could be used as a pharmacologic approach to prevent chemotherapy drug-induced POI, CPM-treated mice were administered one of two mTOR complex (mTORC) inhibitors, either the clinically approved drug everolimus (RAD001) that inhibits mTORC1 or the experimental drug INK128 that inhibits mTORC1 and 2. Both treatments preserved the ovarian reserve, with ovaries containing PMF numbers that were comparable to those in control mice; furthermore, fertility was restored (Goldman et al., 2017). Similar results were obtained with the use of another inhibitor of mTORC1, rapamycin (Zhou et al., 2017; Adhikari et al., 2013).

Tamoxifen. The estrogen receptor modulator tamoxifen is widely used in the treatment of estrogen receptor-positive breast cancers and has been tested as an ovarian protectant against chemotherapy-induced damage. In cultured neonatal rat ovaries, tamoxifen treatment decreased CPM-induced follicle loss, probably through decreased expression of multiple genes related to inflammation, as well as tissue remodelling and vasodilation (Piasecka-Srader et al., 2015). Furthermore, tamoxifen was able to prevent CPM-induced toxicity in PMFs in vivo, protecting the fertility of treated rats (Ting and Petroff, 2010). However, when tamoxifen was given in a randomised-controlled trial to women treated with CPM, methotrexate and 5-fluourouracil, no effect was observed on their ovarian function (Sverrisdottir et al., 2011; Sverrisdottir et al., 2009).

Tyrosine kinase inhibitors. The use of inhibitors for the ATR-CHK2-p63 apoptotic pathway was effective in vitro in protecting primordial follicles from CPM-induced death (Luan et al., 2019).

Cisplatin
Action of Cis and main uses in treatment
CIS is a member of the platinum-based family of compounds. The ability of CIS to inhibit cell division was first identified in the 1960s, and it became the first FDA-approved platinum compound for cancer treatment in 1978 (Kelland, 2007). It is of heavy metal composition and acts as a DNA cross-linking agent that interferes with DNA repair mechanisms, blocks cell division, elicits DNA damage and triggers apoptotic cell death (Dasari and Tchounwou, 2014). The toxicity of CIS is particularly evident in tissues with a rapid cell turnover (Ozcelik et al., 2010). CIS interacts with several different cellular components, but DNA is its primary biological target (Roberts and Pera Jr, 1983). It exerts its cytotoxic mode of action through binding to DNA, by preferentially binding to N-7 positions of guanine and adenine to produce inter- and intra-strand DNA adducts (Kalil and McGuire, 2002). The CIS-induced DNA adducts are recognised by damage recognition proteins which transduce the DNA damage signal downstream and modulate several signal transduction pathways, such as Akt, c-ABL, ATR and MAPK/JNK/ERK (Siddik, 2003; Wang and Lippard, 2005). CIS-induced DNA damage activates cell cycle checkpoints, resulting in cell cycle arrest (Siddik, 2003). Cell cycle checkpoints are necessary to allow the cell repair mechanisms that enable the nucleotide excision repair complex to remove DNA adducts and promote cell survival. When DNA damage is minor, the DNA repair protein PARP detects the presence of DNA strand breaks and activates their repair; if, however, DNA
<table>
<thead>
<tr>
<th>Molecular marker</th>
<th>Drug</th>
<th>Species</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akt</td>
<td>CPM</td>
<td>Mouse</td>
<td>Kalich-Philosoph et al. 2013; Goldman et al. 2017</td>
</tr>
<tr>
<td></td>
<td>CIS</td>
<td>Mouse</td>
<td>Chang et al. 2015; Jang et al. 2016; 2017</td>
</tr>
<tr>
<td>ATM</td>
<td>DOX</td>
<td>Marmoset monkey</td>
<td>Soleimani et al. 2011</td>
</tr>
<tr>
<td>Atr/CHEK1/CK1</td>
<td>CIS</td>
<td>Mouse</td>
<td>Kerr et al. 2012; Nguyen et al. 2018</td>
</tr>
<tr>
<td>Caspase activation</td>
<td>CIS</td>
<td>Human</td>
<td>Bildik et al. 2015; Yuksel et al. 2015</td>
</tr>
<tr>
<td></td>
<td>DOX</td>
<td>Human</td>
<td>Soleimani et al. 2011; Salih et al. 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Marmoset monkey</td>
<td>Salih et al. 2015</td>
</tr>
<tr>
<td>DNA damage assessed by TUNEL</td>
<td>CPM</td>
<td>Rat</td>
<td>Piasecka-Srader et al. 2015; Yeh et al. 2006</td>
</tr>
<tr>
<td></td>
<td>CIS</td>
<td>Mouse</td>
<td>Barberino et al. 2017</td>
</tr>
<tr>
<td></td>
<td>DOX</td>
<td>Mouse</td>
<td>Jang et al. 2017; Ben-Aharon et al. 2010; Morgan et al. 2013; Roti Roti et al. 2014</td>
</tr>
<tr>
<td>DSBs</td>
<td>CPM</td>
<td>Rat</td>
<td>Piasecka-Srader et al. 2015</td>
</tr>
<tr>
<td></td>
<td>DOX</td>
<td>Marmoset monkey Mouse</td>
<td>Salih et al. 2015; Soleimani et al. 2011; Roti Roti et al. 2012, 2014; Xiao et al. 2017</td>
</tr>
<tr>
<td>Foxo3a</td>
<td>CPM</td>
<td>Mouse</td>
<td>Kalich-Philosoph et al. 2013</td>
</tr>
<tr>
<td></td>
<td>CIS</td>
<td>Mouse</td>
<td>Chang et al. 2015; Jang et al. 2016; 2017</td>
</tr>
<tr>
<td>Glutathione</td>
<td>CIS</td>
<td>Rat</td>
<td>Li et al. 2013</td>
</tr>
<tr>
<td></td>
<td>Mouse</td>
<td>Mouse</td>
<td>Barberino et al. 2017</td>
</tr>
<tr>
<td>GSK3</td>
<td>CIS</td>
<td>Mouse</td>
<td>Chang et al. 2015; Jang et al. 2016; 2017</td>
</tr>
<tr>
<td></td>
<td>CIS</td>
<td>Mouse</td>
<td>Gonnifoni et al. 2009; Rossi et al. 2017</td>
</tr>
<tr>
<td></td>
<td>DOX</td>
<td>Marmoset monkey</td>
<td>Salih et al. 2015; Soleimani et al. 2011; Roti Roti et al. 2012, 2014; Xiao et al. 2017</td>
</tr>
<tr>
<td>MAPK, ERK</td>
<td>CIS</td>
<td>Human</td>
<td>Damia et al. 2001; Chang et al. 2015; Jang et al. 2016; 2017</td>
</tr>
<tr>
<td>MMP</td>
<td>DOX</td>
<td>Mouse</td>
<td>Bar-Joseph et al. 2010; Zhang et al. 2017</td>
</tr>
<tr>
<td>mTOR</td>
<td>CPM</td>
<td>Mouse</td>
<td>Kalich-Philosoph et al. 2013</td>
</tr>
<tr>
<td>NOXA &amp; PUMA</td>
<td>CPM</td>
<td>Mouse</td>
<td>Nguyen et al. 2018</td>
</tr>
<tr>
<td></td>
<td>CIS</td>
<td>Mouse</td>
<td>Kerr et al. 2012</td>
</tr>
<tr>
<td>PARP</td>
<td>CIS</td>
<td>Mouse</td>
<td>Morgan et al. 2013; Chang et al. 2015</td>
</tr>
<tr>
<td></td>
<td>DOX</td>
<td>Mouse</td>
<td>Morgan et al. 2013; Bar-Joseph et al. 2010</td>
</tr>
<tr>
<td>Phosphorylation of PTEN</td>
<td>CIS</td>
<td>Mouse</td>
<td>Chang et al. 2015; Jang et al. 2016; 2017</td>
</tr>
<tr>
<td>Pro-apoptotic, anti apoptotic genes (Bax, Bcl-2, p33)</td>
<td>CPM</td>
<td>Mouse</td>
<td>Petrillo, et al. 2011</td>
</tr>
<tr>
<td></td>
<td>CIS</td>
<td>Human</td>
<td>Pascuali et al. 2018</td>
</tr>
<tr>
<td></td>
<td>DOX</td>
<td>Mouse</td>
<td>Damia et al. 2001; Zhang et al. 2017</td>
</tr>
<tr>
<td>Pro-inflammatory cytokines (IL-6, IL-8, TNFα)</td>
<td>CPM</td>
<td>Mouse</td>
<td>Luo et al. 2017</td>
</tr>
<tr>
<td>Reactive oxygen species</td>
<td>CIS</td>
<td>Rat</td>
<td>Ozcan et al. 2015</td>
</tr>
<tr>
<td></td>
<td>DOX</td>
<td>Mouse</td>
<td>Bar-Joseph et al. 2010; Zhang et al. 2017</td>
</tr>
<tr>
<td>SIRT1</td>
<td>CPM</td>
<td>Mouse</td>
<td>Xie et al. 2013; Di Emidio et al. 2017</td>
</tr>
<tr>
<td>StAR, P450scx</td>
<td>DOX</td>
<td>Mouse</td>
<td>Zhang et al. 2017</td>
</tr>
<tr>
<td>Superoxide dismutase reduction</td>
<td>CPM</td>
<td>Rat</td>
<td>Khedr 2015</td>
</tr>
<tr>
<td></td>
<td>CIS</td>
<td>Rat</td>
<td>Melekoglu et al. 2018</td>
</tr>
<tr>
<td></td>
<td>DOX</td>
<td>Mouse</td>
<td>Li et al. 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mouse</td>
<td>Barberino et al. 2017; Bar-Joseph et al. 2010; Zhang et al. 2017</td>
</tr>
<tr>
<td>Tap63</td>
<td>CIS</td>
<td>Mouse</td>
<td>Gonnifoni et al. 2009; Kim et al. 2018; Tuppi et al. 2018</td>
</tr>
</tbody>
</table>
damage is extensive and DNA repair is not completed, PARP activation can initiate cell death through apoptosis or necrosis (Soldani and Scovasi, 2002). In addition to binding covalently to DNA, CIS can also bind to nuclear and cytoplasmic proteins which can cause adverse toxic effects in patients (Kall and McGuire, 2002; Chovanec et al., 2017), and it is possible that these mechanisms may add to its gonadotoxicity.

**Effect of CIS on the ovary**

**Human ovary studies.** There are limited clinical data available on the ovarian toxicity of CIS. Female patients treated with CIS have usually received it as part of a multiple-drug regimen, making it difficult to elucidate exact mechanisms of CIS-induced ovarian toxicity. CIS is generally considered to have moderate ovarian toxicity, although, to the best of our knowledge, only one clinical study has reported this, finding mild to moderate rates of amenorrhea and an increased risk of ovarian failure and infertility following treatment with a multi-drug regimen that included CIS (Maneschi et al., 1994). Others have found no detrimental effects on fertility following CIS treatment, particularly for germ cell tumours (Brewer et al., 1999; Weinberg et al., 2011), although effects on male fertility are clear (Chow et al., 2016). CIS-induced damage has been found in studies that have cultured human ovarian cortical pieces or granulosa cells in its presence, resulting in a decrease in follicle numbers and a reduction in steroidogenic activity (Bildik et al., 2015; Yuksel et al., 2015).

**Non-human ovary studies.** Most of the information on the ovarian toxicity of CIS has been derived from animal studies. There is a growing body of evidence demonstrating a loss of ovarian reserve and increased follicular atresia following CIS exposure in mouse and rat ovaries (Gonfloni et al., 2009; Yuksel et al., 2015; Kim et al., 2013; Morgan et al., 2013; Rossi et al., 2017; Nguyen et al., 2018), with immature oocytes being particularly susceptible (Rossi et al., 2017; Morgan et al., 2013). Studies examining effects of CIS exposure on follicles frequently report the loss of PMFs, through PMF death directly and/or indirectly due to accelerated activation; in either case, this would ultimately lead to POI (Yucebilgin et al., 2004; Chang et al., 2015). If CIS targets growing follicles, their death will result in decreased secretion of factors, such as AMH, that can inhibit PMF activation, and CIS has been shown to reduce circulating AMH and inhibin-α levels, corresponding with a decrease in the percentage of AMH-positive follicles (Yeh et al., 2006; Li et al., 2014; Ozcan et al., 2015; Yeh et al., 2008).

**Molecular pathways of CIS-induced ovarian damage**

Despite the therapeutic potential of CIS being discovered over 40 years ago, its mechanisms of action are still not fully understood. The proposed pathways to damage include CIS eliciting DNA damage that leads to the activation of apoptotic pathways through the p53 family of signalling and damage through oxidative stress and production of free radicals (Table 1). Exposure to CIS increases DNA damage in ovarian cells, resulting in apoptosis, as is evident from increased DNA damage, TUNEL and activation of apoptotic genes, such as caspase 3 (Bildik et al., 2015; Yuksel et al., 2015; Barberino et al., 2017; Jang et al., 2017). The tumour-suppressor p53 protein and members of its family play a crucial role in the degree to which CIS-induced DNA damage is repaired, ultimately determining cell fate. ATR, a kinase involved in checkpoint activation, is activated by CIS, and in turn can activate p53, as well as specific pathways of the MAPK cascade (Damia et al., 2001). The p53 homologue p63, specifically its isoform TAp63α, is expressed in dormant and growing oocytes (Suh et al., 2006). This protein is a key mediator of the DNA damage response within the ovary. CIS activates TAp63α through an ATR/CHEK1/CK1 pathway (Tuppi et al., 2018; Kim et al., 2018); this increases the expression of PUMA and NOXA, leading to apoptosis of those oocytes that are irreparably injured following CIS treatment, directly inducing follicle death (Kerr et al., 2012; Nguyen et al., 2018). CIS-exposure also leads to increased reactive oxygen species and a decrease in the ovarian antioxidant capacity (Ozcan et al., 2015). This has been correlated with decreased activities of the antioxidant enzyme superoxide dismutase (Bansod et al., 2017) and the thiol anti-oxidant glutathione (GSH) following CIS exposure (Li et al., 2013; Barberino et al., 2017). Exposure to CIS results in increased phosphorylation of key proteins in the PTEN/Akt/FOXO3a pathway, including PTEN, Akt, GSK3, FOXO3a and ERK, leading to nuclear export of FOXO3a which in turn suppresses its transcription activities, together leading to accelerated activation of PMFs (Jang et al., 2016; Chang et al., 2015).

**Agents used to protect ovaries from CIS-induced damage**

There is now a range of agents aiming to protect the ovary against CIS-induced damage, preventing direct loss of PMFs, accelerated PMF activation or follicular atresia (Fig. 1B, Table II). However, there are no published data on the potential of any of these to protect against damage in the human ovary.

**Tyrosine kinase inhibitors.** The p53 family member TAp63α is responsible for DNA damage-induced apoptosis of oocytes within PMFs. TAp63α is the only isoform of TAp63 expressed by the oocyte and becomes activated after DNA damage; tyrosine kinase signalling is involved in this key regulatory pathway (Suh et al., 2006). Recently, CHK2 and the executioner kinase CK1 have been identified as important for the elimination of mouse oocytes following double-stranded breaks in DNA (Bolcun-Filas et al., 2014; Tuppi et al., 2018), and their function is essential for downstream activation of TAp63 (Kehrlhoesser et al., 2018). In vitro, pharmacological inhibition of CHK2/CK1 was shown to be effective at rescuing oocytes from TAp63-mediated apoptosis induced by CIS or by DOX (see below) or following γ-irradiation (Rinaldi et al., 2017; Tuppi et al., 2018). The same results have been obtained using inhibitors of ATM and ATR (Tuppi et al., 2018; Kim et al., 2018), indicating that the TAp63 pathway could be an effective target for developing protective strategies in oncofertility. Pharmacological inhibitors of ATM, ATR, CHK2 and CK1 are already being used in preclinical and clinical trials (Rundle et al., 2017), potentially expediting their application to this field, while inhibitors of the downstream targets of TAp63α, NOXA or PUMA still need to be discovered.

Imatinib is an inhibitor of the oncogenic BCR-Abl tyrosine kinase enzyme and is itself used in the treatment of cancers, such as chronic myeloid leukaemia and gastro-intestinal stromal tumours. Data on the efficacy of imatinib against damage by CIS have been conflicting, with some studies finding protective effects (Gonfloni et al., 2009; Maiani et al., 2012; Kim et al., 2013), and others finding either no evidence of protection or even deleterious effects (Kerr et al., 2012; Zamah et al., 2011). All published studies have been carried out using the mouse as a model, and there are no data on effects on the human ovary. Recent work examining the mechanism of activation of TAp63α has demonstrated that imatinib is able to protect oocytes from CIS-induced death without interfering with TAp63α tetramerization (Tuppi et al., 2018). The same conclusion was reached in another study
<table>
<thead>
<tr>
<th>Protectant</th>
<th>Drug</th>
<th>Target action</th>
<th>Species</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMH/MIS</td>
<td>CPM</td>
<td>Accelerated PMF activation</td>
<td>Mouse</td>
<td>Kano et al. 2016</td>
</tr>
<tr>
<td>DOX</td>
<td>Accelerated PMF activation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carboplatin</td>
<td>CPM</td>
<td>Accelerated PMF activation</td>
<td>Mouse</td>
<td>Sonigo et al. 2018</td>
</tr>
<tr>
<td>ATM inhibitors:</td>
<td>CIS</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Tuppi et al. 2018</td>
</tr>
<tr>
<td>ETP-46464</td>
<td>DOX</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Kim et al. 2018</td>
</tr>
<tr>
<td>KU55399</td>
<td>CPM</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Kim et al. 2018</td>
</tr>
<tr>
<td>ATR inhibitors:</td>
<td>CIS</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Tuppi et al. 2018</td>
</tr>
<tr>
<td>ETP-46464</td>
<td>DOX</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Luan et al. 2019</td>
</tr>
<tr>
<td>AZD6738</td>
<td>CPM</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Kalich-Philosoph et al. 2013</td>
</tr>
<tr>
<td>AS101</td>
<td>CPM</td>
<td>Accelerated PMF activation</td>
<td>Mouse</td>
<td>Di Emidio et al. 2017</td>
</tr>
<tr>
<td>Bortezomib</td>
<td>DOX</td>
<td>Atresia</td>
<td>Mouse</td>
<td>Rotti Rotti et al. 2014</td>
</tr>
<tr>
<td>Ceramide-1-phosphate</td>
<td>CPM</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Pascual et al. 2018</td>
</tr>
<tr>
<td>CHK2 inhibitors:</td>
<td>CIS</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Rinaldi et al. 2017</td>
</tr>
<tr>
<td>BML277</td>
<td>DOX</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Tuppi et al. 2018</td>
</tr>
<tr>
<td>LY2603618</td>
<td>CPM</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Luan et al. 2019</td>
</tr>
<tr>
<td>LY2606368</td>
<td>CPM</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Tuppi et al. 2018</td>
</tr>
<tr>
<td>CK1 inhibitors:</td>
<td>CIS</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Tuppi et al. 2018</td>
</tr>
<tr>
<td>MK-8776</td>
<td>DOX</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Tuppi et al. 2018</td>
</tr>
<tr>
<td>CHIR-124</td>
<td>CPM</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Tuppi et al. 2018</td>
</tr>
<tr>
<td>PMF670462</td>
<td>CPM</td>
<td>Accelerated PMF activation</td>
<td>Mouse</td>
<td>Di Emidio et al. 2017</td>
</tr>
<tr>
<td>PMF4800567</td>
<td>CPM</td>
<td>Accelerated PMF activation</td>
<td>Mouse</td>
<td>Kropp et al. 2015</td>
</tr>
<tr>
<td>PMF5006739</td>
<td>CPM</td>
<td>Accelerated PMF activation</td>
<td>Mouse</td>
<td>Jang et al. 2017</td>
</tr>
<tr>
<td>Crocetin</td>
<td>CPM</td>
<td>Accelerated PMF activation</td>
<td>Mouse</td>
<td>Kim et al. 2013</td>
</tr>
<tr>
<td>Dexrazoxane</td>
<td>DOX</td>
<td>Atresia</td>
<td>Mouse</td>
<td>Maiani et al. 2012</td>
</tr>
<tr>
<td>Ghrelin</td>
<td>CIS</td>
<td>Accelerated PMF activation</td>
<td>Mouse</td>
<td>Jang et al. 2017</td>
</tr>
<tr>
<td>G-CSF</td>
<td>CIS</td>
<td>Atresia</td>
<td>Mouse</td>
<td>Skaznik-Wikiel et al. 2013</td>
</tr>
<tr>
<td>Imatinib</td>
<td>CIS</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Akdemir et al. 2014</td>
</tr>
<tr>
<td>Luteinizing Hormone</td>
<td>CIS</td>
<td>Direct loss of PMFs</td>
<td>Mouse</td>
<td>Kim et al. 2013</td>
</tr>
<tr>
<td>MDR1</td>
<td>CPM</td>
<td>Delivery to ovary</td>
<td>Mouse</td>
<td>Brayboy et al. 2013; 2017</td>
</tr>
<tr>
<td>Melatonin</td>
<td>CIS</td>
<td>Accelerated PMF activation</td>
<td>Mouse</td>
<td>Wang et al. 2018</td>
</tr>
<tr>
<td>Mesna</td>
<td>CIS</td>
<td>Atresia</td>
<td>Rat</td>
<td>Jang et al. 2016</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>CIS</td>
<td>Atresia</td>
<td>Rat</td>
<td>Li et al. 2013</td>
</tr>
<tr>
<td>mTORC inhibitors:</td>
<td>CPM</td>
<td>Accelerated PMF activation</td>
<td>Mouse</td>
<td>Altun et al. 2013</td>
</tr>
</tbody>
</table>

(Continued)
which generated a conditional knockout mouse with an oocyte-specific deletion of Abl1 and Abl2; ovaries from these mice treated with CIS show no protection against apoptosis (Kim et al., 2018). Imatinib is not an inhibitor of a specific tyrosine kinase signalling pathway, but can affect a range of pathways, including those downstream of c-Kit, the PDGF receptor and, to a lesser extent, c-Src (Seeliger et al., 2007). As tyrosine kinase signalling is involved in several key regulatory processes in the ovary, it could be that the mixed reports about the action of imatinib results from both beneficial and detrimental effects on the ovary due to its range of actions, and that inhibiting specific tyrosine kinase signalling pathways could provide the ovary with more effective protection.

Luteinizing Hormone. In addition to its cardinal roles in ovulation and induction and maintenance of the corpus luteum and its use in fertility programs for assisted reproduction techniques, recent research has shown that luteinizing hormone (LH) is also able to protect PMFs from the deleterious effects of CIS in prepubertal mice (Rossi et al., 2017). When CIS is administered concomitantly with LH, there is little degeneration of PMFs and mice maintain their fertility. LH is able to stimulate the DNA repair mechanisms and at the same time block CIS-induced apoptotic pathways in oocytes, an effect shown to be indirect, since the oocyte lacks LH receptors. LH does not counteract the activation/tetramerization of TAp63α (Rossi et al., 2017; Tuppi et al., 2018); its mechanism of action remains to be elucidated.

Melatonin and ghrelin. Melatonin (N-acetyl-5-methoxytryptamine) is a hormone synthesised and secreted mainly by the pineal gland (Venegas et al., 2012; Reiter et al., 2013; Reiter et al., 2014). Apart from its use in sleep disorders, melatonin can also reduce the side effects of anticancer drugs by removing hydrogen peroxide, singlet oxygen, superoxide anion radicals and peroxyl radicals (Casado-Zapico et al., 2010; Pariente et al., 2016). Its potential protective effect was first investigated in the male; in mouse testis, melatonin prevents CIS-induced testicular toxicity by scavenging free-radical products (Atessahn et al., 2006). More recently, protection has also been found in the female, where co-administration of CIS and melatonin has been shown to lead to a reduction in TUNEL in granulosa cells, resulting in reduced atresia of growing follicles and suppression of phosphorylation of the PTEN/AKT/FOXO3a pathway, thus limiting PMF activation (Jang et al., 2016).

Ghrelin is a hormonal peptide produced by cells in the gastrointestinal tract. Although it is known as the “hunger hormone,” increasing evidence supports a more complex role in the regulation of metabolism. As with melatonin, ghrelin has protective activity against CIS-induced testicular damage (Garcia et al., 2015; Whirledge et al., 2015). Oocytes within PMFs express receptors for both ghrelin and melatonin, and the combination has been tested for activity against CIS-induced damage (Jang et al., 2017). Co-administration of the two hormones blocks PMF loss by reducing PTEN and FOXO3a phosphorylation. Given the presence of their receptors in the oocyte, it is possible that these hormones have a direct action on PMFs, potentially affecting their capacity to remain in a quiescent state.

Antioxidants. Four different antioxidants, mesna, mirtazapine, resveratrol and sildenafil citrate, have been tested for their protective effects on the ovarian reserve of rats treated with CIS (Li et al., 2013; Ozcan et al., 2015; Taskin et al., 2015; Altuner et al., 2013). Mesna, sildenafil citrate and resveratrol prevented the loss of AMH-positive follicles; mirtazapine also improved fertility. The antioxidative enzymatic activity of superoxide dismutase and glutathione were increased after co-administration of mesna or mirtazapine with CIS. These results indicate that the maintenance of low levels of free radicals in the ovary is important to promote the survival of the ovarian reserve.

mTORC inhibitors. Everolimus prevents the loss of primordial follicle in cisplatin chemotherapy-induced treated mice, in which the activation of the PI3K/PTEN/AKT pathway was detected (Chang et al., 2015; Tanaka et al., 2018).

**Doxorubicin**

**Action of DOX and main uses in treatment**

The anthracycline antibiotic DOX (14-hydroxydaunomycin) is a commonly used chemotherapy agent often known by its main trade names, Adriamycin or Rubex. It was originally isolated from Streptomyces peucetius in the 1970s and is now used to treat a large range of cancers,
including breast, lung, gastric, ovarian, bladder, thyroid, leukaemia, sarcoma, lymphoma, neuroblastoma, Wilms’ tumours and paediatric cancers (Blum and Carter, 1974; Roti Roti et al., 2014; Xiao et al., 2017). The main and most widely recognised mechanism of DOX is the inhibition of the nuclear enzyme topoisomerase II. Topoisomerase II prevents supercoiling and twisting of the DNA during replication by producing double-strand nick and resealing of the cleaved DNA and is, therefore, particularly abundant in the G2/M cell cycle phase transition. DOX prevents topoisomerase II-DNA complex formation after the nicking phase, with an accumulation of DNA fragments which ultimately induces cell death. In addition, DOX stimulates the production of oxygen-free radicals and other reactive oxygen species (Tokarska-Schlattner et al., 2006) and is responsible for mitochondrial dysfunction (Clementi et al., 2003). Both free radical production and mitochondrial damage have a negative impact on cellular metabolism and membrane integrity, resulting in severe side effects. DOX also intercalates into DNA, impairing DNA replication and RNA and protein synthesis (Kiyomiya et al., 1998; Thorn et al., 2011; Paik et al., 1998; Zhang et al., 2017).

Effect of DOX on the ovary

Human ovary studies. Amongst other off-target effects, infertility has been reported in both adult and childhood patients as a consequence of regimens that include the use of DOX (Lipshultz et al., 2017). The probability of amenorrhea following treatments that includes the use of DOX ranges from 7% to 80%, primarily depending on the age of the woman at the time of exposure (Ben-Aharon et al., 2010; Letourneau et al., 2012; Knobf, 2006). However, as with many studies that investigate the effect of chemotherapy on fertility by examining time until menses resumption, these findings may not accurately reflect the full degree of gonadotoxic damage or the total effect on fertility lifespan, since full examination of either requires very long-term follow-up studies. Moreover, as with CPM and CIS, it is difficult to clearly isolate the role of a single drug, such as DOX when drugs are administered in combination. Only two studies have investigated the direct role of DOX on the human ovary (Li et al., 2014; Soleimani et al., 2011), with both studies using human ovarian cortex examined either in vitro and/or after xenotransplantation into immunocompromised mice. This work has also highlighted DOX-induced damage to the microvasculature as well as necrosis of the ovarian stromal tissue (Soleimani et al., 2011).

Non-human ovary studies. DOX affects cortical blood vessels in the mouse model, as well as in the human ovary, inducing fibrosis (Ben-Aharon et al., 2010). DOX has been shown to cross the follicle basement membrane and accumulate in the DNA and mitochondria of the oocyte (Bar-Joseph et al., 2010). A dose-dependent depletion of follicles, both primordial and early growing, has been found in many studies (Morgan et al., 2013; Perez et al., 1997; Roti Roti and Salih, 2012; Roti Roti et al., 2014; Aliotta et al., 2005; Tuppi et al., 2018). Later stages of follicle development are also affected by DOX treatment, resulting in a reduction in secondary and antral follicles. Furthermore, DOX decreases the ovulation rate, and although the ovulated oocytes appear morphologically normal, blastocyst number (Bar-Joseph et al., 2010), litter size (Kropp et al., 2015), and pup birth weight (Roti Roti et al., 2014) are reduced. The main DOX-induced damage in follicles appears to be in the mitotically active granulosa cells, with damage to oocytes being a consequence of follicle disruption (Bar-Joseph et al., 2010; Morgan et al., 2013; Roti Roti et al., 2012; Roti Roti et al., 2014; Wang et al., 2018). Ultimately, DOX exposure causes a reduction in fertile lifespan (Roti Roti et al., 2014).

Molecular pathways of DOX-induced ovarian damage

Apoptosis is the main, and certainly the most studied, process of cell death triggered by DOX in the ovary, although the exact pathway(s) is still somewhat unclear. Exploration of DOX-triggered apoptosis has made possible identification of several markers of programmed cell death in both human and animal model tissues (Table I). PMFs in DOX-treated human ovarian cortex show increased expression of γH2AX and cleaved caspase 3 (Soleimani et al., 2011). Mouse granulosa and stromal/thecal cells isolated from growing follicles, as well as oocytes, have double-strand DNA breaks after DOX injection (Roti Roti et al., 2014; Roti Roti et al., 2012; Xiao et al., 2017). Double-strand breaks and γH2AX are also increased in antral follicles in marmoset monkey ovary exposed to DOX (Salih et al., 2015), as are metaphase II oocytes which undergo apoptosis after DOX exposure in vitro (Perez et al., 1997; Soleimani et al., 2011). As downstream effectors of the apoptotic pathway, the death regulating genes Bax and Bcl-2 appeared to be involved (Zhang et al., 2017), with oocytes collected from Bax-deficient animals resistant to DOX-induced apoptosis (Perez et al., 1997). As previously described, TAp63α becomes activated after oocyte DNA damage, and DOX can act on the TAp63 pathway to directly induce PMF loss (Tuppi et al., 2018). Granulosa cells exposed in vitro to DOX exhibit an increase in expression of p53 mRNA (Zhang et al., 2017), while the neonatal mouse ovary exhibits an increase in the apoptotic marker PARP (Morgan et al., 2013). As a late marker in the apoptotic pathway, TUNEL-positive cells are increased when the ovary is exposed to DOX (Ben-Aharon et al., 2010; Morgan et al., 2013; Roti Roti et al., 2014). Other molecular pathways have also been suggested to play a role in the gonadotoxicity caused by DOX. Accumulation of reactive oxygen species and superoxides, along with a decrease in mitochondrial membrane potential, have been observed in DOX-treated granulosa cells, suggesting involvement of oxidative stress mitochondrial-mediated apoptosis (Bar-Joseph et al., 2010; Zhang et al., 2017). Only preliminary indications are available as to whether the PI3K signalling pathway is activated by DOX, with AKT I but not PTEN expression increased in marmoset ovary (Salih et al., 2015).

Agents used to protect ovaries from DOX-induced damage

Protectants against ovarian damage by DOX resulting in reduced activation of PMFs or follicular atresia have all been developed using the mouse as a model (Fig. 1B, Table II). However, none of these have been tested for their ability to protect against damage in the human ovary.

Sphingosine-1-phosphate. Morita et al. (2000) reported the first use of the sphingolipid S1P as a protector from oocyte apoptosis when induced by exposure to 0.1 Gy of ionizing radiation. To confirm the role of S1P, knockout mice lacking the acid sphingomyelinase gene were generated; in that mouse, germ cells were resistant to apoptosis and to DOX-induced DNA damage. In the human ovary, S1P prevents DOX-induced apoptotic follicle death in ovarian xenographs (Li et al., 2014; Meng et al., 2014).

Dexrazoxane. The iron-chelating EDTA derivative dexrazoxane can reduce DOX-induced DNA double-strand breaks, by chelating iron...
and inhibiting topoisomerase II. It is already used in cancer therapies, protecting the heart and skin from other off-targets effects of DOX without altering the effectiveness of DOX as a chemotherapeutic drug (Reichardt et al., 2018; Langer, 2014). In vitro and in vivo co-administration of DOX and dextrazoxane reduces ovarian DNA double-strand breaks and granulosa cell death, with dextrazoxane pre-treatment significantly restoring fertility in vivo (Kropp et al., 2015).

Bortezomib. Proteasome inhibitors have been developed as anti-cancer agents and several are either approved for clinical use to treat melanomas and lung cancers or currently in trials (Kouroukis et al., 2014). MG-132 and bortezomib both directly compete with DOX for proteasome binding, thus preventing nuclear accumulation of DOX in a leukemia cell line and also in cardiac cells (Amiri et al., 2004; Huang et al., 2012; Pajonk et al., 2005). Female mice treated in vivo with bortezomib show reduced DOX-induced DNA damage in all ovarian cell types, resulting in reduced preantral follicle atresia. Fertility studies have shown that bortezomib pretreatment leads to an increase in litter size and pup weight following DOX treatment, thus improving post-chemotherapy fertility (Roti Roti et al., 2014).

Tyrosine kinase inhibitors. Pharmacological inhibition of ATM, ATR, CHK2 or CK1 are all effective in vitro at rescuing oocytes from DOX-induced TP53-mediated apoptosis (Rinaldi et al., 2017; Tuppi et al., 2018), although imatinib was not found to confer protection against DOX-induced damage to ovarian follicles (Morgan et al., 2013). The kinetics of DOX action are reported to be faster than that of CIS, probably because DOX directly induces double-strand breaks while CIS creates DNA adducts (Tuppi et al., 2018).

Protective agents acting independently of specific chemotherapy drug actions

Most of the research into potential protectants discussed above has been designed with the aim of protecting the ovary against a specific chemotherapy drug or drug class. Other potential protectants should, at least in theory, provide protection against a wide range of chemotherapy drugs, either by blocking a common damage pathway or by reducing the delivery of drugs to the ovary.

Protectants against specific damage pathways

Protection against increased PMF activation: AMH. AMH is primarily produced by granulosa cells of developing follicles and can inhibit activation of PMFs, at least in rodents. The situation in the human ovary is less clear, with publications showing both initiation and suppression of preovulatory follicle growth in response to AMH (Carlsson et al., 2006; Schmidt et al., 2005). The hypothesis that accelerated activation of PMFs, following the chemotherapy drug-induced death of growing follicles, is an important pathway leading to depletion of the PMF pool has led to the suggestion that AMH treatment might be an effective protectant against a wide range of drugs. Two recent studies have investigated this, examining the effectiveness of AMH at protecting the mouse ovary from CPM- and DOX-induced damage, along with damage from the platinum-containing agent carboplatin (Kano et al., 2017; Sonigo et al., 2018).

Kano and colleagues showed a significant protective effect of AMH administration from damage induced by each of CPM, DOX and carboplatin, particularly in terms of protecting the PMF pool. AMH appeared most effective against DOX-induced damage, but it is difficult to draw conclusions from this study about the comparative effectiveness of AMH against the different drugs, since the doses that were administered for each chemotherapy drug resulted in a lowering of the PMF pool to a different extent in each case (Kano et al., 2017). Nonetheless, this work highlights the importance of studying a range of chemotherapy drugs in this research.

More recently, Sonigo et al. (2018) also found that AMH reduced the loss of follicles induced by CPM, with protection against the reduction in number of oocytes that could be recovered following ovarian stimulation, although an effect on fertility was not shown. That study also provided data suggesting that AMH regulates FOXO3a phosphorylation and induces autophagy in ovaries. These results lead the authors to discuss the hypothesis that AMH reduces PMF loss induced by CPM through autophagy activation.

Both studies highlight the potential value of AMH as a protective agent in the field of oncofertility, with activity against several chemotherapeutic drugs. Additionally, since it is thought to be only involved in the regulation of reproductive function, it may not interfere with the therapeutic effects of chemotherapy.

Protection of ovarian blood vessels: Granulocyte-colony stimulating factor. Granulocyte-colony stimulating factor (G-CSF) is a cytokine that stimulates hematopoietic progenitor cell growth and has been successfully used alongside cancer therapy to overcome chemotherapy-induced myelosuppression (Ciurea et al., 2019). G-CSF increases microvessel density and decreases follicle loss in CPM- and busulfan-treated female mice compared to control groups; moreover, G-CSF can partially restore fertility (Skaznik-Wiik et al., 2013). G-CSF, with or without stem cell factor, also extends the time until the onset of POI in mice treated with alkylating chemotherapy (Skaznik-Wiik et al., 2013). An effect has also been seen against CIS in the rat, where all follicle counts (primordial, primary, secondary and tertiary) and serum AMH levels were significantly increased in the G-CSF-CIS treated group compared to the control group (Akdemir et al., 2014). Despite the clinical use of G-CSF in cancer treatment, making it a good ovarian protectant candidate to test clinically, there are no data on the effectiveness of G-CSF at protecting the human ovary against damage by chemotherapy drugs.

Protectants against chemotherapy drug delivery to the ovary

Uregulation of multidrug resistance gene 1. Multidrug resistance gene 1 (MDRI) is a phase three drug transporter enzyme involved in the metabolism, elimination and detoxification of chemotherapy drugs. By promoting the transport and efflux of various lipid-soluble anti-cancer agents, upregulation of MDRI has been linked with resistance to chemotherapy (Fojó et al., 1987; Lepper et al., 2005). Retroviral transduction has been used to upregulate MDRI in a granulosa cell line in order to reduce the uptake of chemotherapeutic agents into these cells. This upregulation of MDRI was reported to protect granulosa cells from the toxic effects of both DOX and paclitaxel in a dose-dependent manner, with the MDRI-transduced granulosa cells showing significantly increased cell survival following treatment with either drug (Salih, 2011). These results are supported by other studies, where the inhibition of MDR transporters in human and mouse oocytes, as well as deletion of the gene in mice, has led to increased susceptibility to CPM toxicity (Brayboy et al., 2017; Wang et al., 2018; Brayboy et al., 2013).
A novel approach to ovarian protection, and indeed to reduce other toxicities, has been to encapsulate the chemotherapeutic drug arsenic trioxide inside nanoparticles that specifically target cancer cells (Ahn et al., 2013), with the result being decreased plasma levels and toxicity of these drugs. This strategy could be applied to other chemotherapeutic agents, to target more specifically target the cancer cells while protecting the gonads from damage.

**Conclusion**

The last decade has seen the development of a number of potential methods for protecting the ovary against damage from chemotherapy drugs (Fig. 1B, Table II). Such protectants are needed not only to preserve fertility but also to allow females to retain endocrine function and avoid the detrimental health consequences of POI. Most of that work has been carried out using rodent models, primarily the mouse. One strategy for such animal model studies, which has been used infrequently to date, is to examine protectants in a animal that has cancer (Qin et al., 2018), although this could be very effective. Surprisingly, few studies to date have examined the effectiveness of potential protectants directly in human ovarian tissue, although this strategy has been used to investigate the potential of S1P and tamoxifen to protect against CPM-induced damage. In the near future, it is vital for more studies to determine the effect of these drugs in the human ovary and/or for research to use large, monovulatory mammalian species as models. With that work, the hope then is that some of these protectants will be able to be taken into clinical trials. Clearly, any protectant will need to not only shield the ovary from damage but will also need to be shown not to interfere with the efficacy of the chemotherapy treatment. In light of that, potential protectants that are already administered to cancer patients are of particular interest here, including AS101, imatinib and G-CSF.

Notwithstanding our improved understanding of female reproduction in recent years, we still do not know what determines whether or not an individual PMF will undergo activation and initiate growth at a particular time. A number of potential protectants under current investigation involve manipulating the Akt pathway, stressing the importance of greater understanding of its role, including in the human ovary. The expression of p-Akt in mice pups is usually restricted to stromal cells and often the expression of p-Akt is by Western blotting on whole ovaries. Nevertheless, only recently, its co-expression in primary oocytes upon exposure to CPM with the activated apoptotic protein PARP was shown (Luan et al., 2019). We also have only a limited understanding of what constitutes a healthy oocyte, and it is of course vital that any clinically used protectant maintains the health and developmental competence of the oocyte. Therefore, the implications for the developmental competence of oocytes exposed to potential protectants, as well as chemotherapy agents, should be explored, taking into consideration the long reproductive lifespan of women, and the background deterioration of oocyte “quality” and repair mechanisms with age (Kujjo et al., 2011; Vandenbroucke et al., 2017; Momen et al., 2017). CPM treatment in particular is well established to result in abnormalities in rodent offspring following sub-sterilising dose exposure, although there is no evidence of increased risk of abnormalities or of genotoxicity in humans following maternal radiotherapy or chemotherapy exposure (Signorello et al., 2012; Winther et al., 2009; Winther et al., 2012; Vandenbroucke et al., 2017). Future studies will need to examine whether or not there is evidence of such effects after administration of protectants, as well as of chemotherapeutics. Epigenetic inheritance through the germ line or the potential for transgenerational effects should also be considered in future studies (Wei et al., 2015; Clarke and Vieux, 2015; Di Emidio et al., 2019). It is notable that most protectants under investigation focus on protecting against ovarian follicle death but it is also important to bear in mind that the stromal environment contributes to the health of follicles, and not focus research exclusively on direct effects on the follicles. At present, protecting the ovary against stromal damage appears to have had little attention (Fig. 1B), possibly one consequence of the majority of research using rodents as models. Overall, however, recent years have seen the development of many potential protectants, acting on a wide range of different pathways and with evidence for efficacy in the mouse model, offering hope for the subsequent development of clinically effective treatment.

**Acknowledgement**

Thanks to Ronnie Grant for help with the figure.

**Authors’ roles**

All authors contributed to the study design, literature analysis and drafting of the article, as well as critical reading and editing.

**Funding**

This work was supported by European Society of Human Reproduction and Embryology grant 2014-01, with some work undertaken in the MRC Centre for Reproductive Health, funded by MRC Centre grant MR/N022556/1. RAA has received fees and research support from Roche Diagnostics.

**Conflict of interest**

RAA reports personal fees and non-financial support from Roche Diagnostics, outside of the submitted work. All other authors confirm that they have no conflict of interest.

**References**


Protecting the ovary against chemotherapy


Protecting the ovary against chemotherapy


Whirlode SD, Garcia JM, Smith RG, Lamb DJ. Ghrelin partially protects against cisplatin-induced male murine gonadal toxicity in a GHSR-ia-dependent manner. *Bioiol Reprod* 2015;92:76.


of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells. *Hum Reprod* 2015;30:2926–2935.

